1. Volume 375, Issue 9722, Pages 1278-1286 (April 2010)
Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort 
Dr AS Walker, PhD, D Ford, PhD, Prof CF Gilks, FRCP, P Munderi, MBChB, F Ssali, MBChB, A Reid, MBChB, Prof E Katabira, FRCP, Prof H Grosskurth, PhD, Prof P Mugyenyi, FRCP, Prof J Hakim, FRCP, Prof JH Darbyshire, FRCP, Prof DM Gibb, MD, Prof AG Babiker, PhD 
The Lancet 
Volume 375, Issue 9722, Pages (April 2010)
DOI: /S (10)
Copyright © 2010 Elsevier Ltd Terms and Conditions

2. Figure
Effect of co-trimoxazole prophylaxis with ART from weighted models
(A) Clinical outcomes on ART. (B) Predicted survival on ART*. ART=antiretroviral therapy. CTX=co-trimoxazole. OR=odds ratio. *Assumes co-trimoxazole prophylaxis has different effects in weeks 0–72 (OR 0·49) and after 72 weeks (OR 0·96) on ART. Risks were estimated for a woman aged 30–40 years starting ART (lamivudine-zidovudine plus tenofovir) in 2003 with WHO stage 3 disease, haemoglobin 115 g/L, BMI >21 kg/m2, no WHO stage 3 or 4 event in the 4 weeks before starting ART, and CD4 count 15 or 150 cells per μL.
The Lancet  , DOI: ( /S (10) )
Copyright © 2010 Elsevier Ltd Terms and Conditions